Last updated: March 17, 2026
What is the drug identified by NDC 53746-0669?
NDC 53746-0669 corresponds to Remimazolam, marketed by Acacia Pharma. It is an ultra-short-acting benzodiazepine used as a sedative agent, primarily for procedural sedation and induction of anesthesia.
Market Overview
Therapeutic Indications and Usage
Remimazolam serves as an alternative to drugs like midazolam and etomidate. Its advantages include rapid onset and offset, minimal accumulation, and the absence of active metabolites.
Current Market Penetration
- Target Population: Estimated to be around 30 million annually in the U.S. for procedural sedation and anesthesia induction.
- Market Penetration: Limited since FDA approval in 2020; mainly adopted in hospitals with advanced anesthesia services.
Competitive Landscape
| Drug |
Status |
Market Share (2022) |
Advantages |
Limitations |
| Remimazolam |
New entrant |
10-15% |
Rapid recovery, fewer side effects |
Higher cost |
| Midazolam |
Established |
50-60% |
Cost-effective, familiar |
Longer duration, slower clearance |
| Etomidate |
Specialist use |
15-20% |
Hemodynamic stability |
Adrenal suppression risk |
Market Drivers
- Preference for rapid emergence anesthesia.
- Growing outpatient and ambulatory procedures.
- Focus on drug safety profiles.
Market Challenges
- High acquisition cost.
- Limited formulary placement outside major institutions.
- Need for practitioner training on new agent.
Price Analysis
Current Pricing
| Region |
Average Price per Vial |
Packaging |
Cost Drivers |
| United States |
$300 - $350 |
10 mg / 10 mL vial |
Manufacturing costs, market exclusivity |
| Europe |
€250 - €300 |
10 mg / 10 mL vial |
Regulatory fees, currency exchange |
| Asia-Pacific |
$200 - $275 |
10 mg / 10 mL vial |
Distribution costs, competition |
Price Comparison with Competitors
- Midazolam: $5 - $10 per dose.
- Etomidate: $150 - $200 per dose.
- Propofol: $8 - $15 per dose.
Remimazolam’s higher price reflects its patent exclusivity and advanced safety profile; however, price sensitivity remains a concern in cost-conscious markets.
Future Price Trends (2023–2027)
- Price stabilization expected in the U.S. due to patent exclusivity ending around 2030.
- Potential discounts driven by formulary negotiations and competition introductions.
- Emerging biosimilar or generics could drive prices down by 2028.
Market Projections
| Year |
Estimated Market Size (USD millions) |
Growth Rate |
Major Factors Affecting Growth |
| 2023 |
$250 |
12% |
Increasing adoption, hospital preferences |
| 2024 |
$280 |
12% |
Expanded indications, more facilities |
| 2025 |
$320 |
14% |
Broader insurance coverage |
| 2026 |
$370 |
15% |
Competitive pressures, price adjustments |
| 2027 |
$430 |
16% |
Market expansion, new regional approvals |
Key Market Segments
- Hospital-based anesthesia services.
- Outpatient surgical centers.
- Emergency departments.
Geographic Outlook
| Region |
Growth Potential |
Barriers |
| North America |
High |
Cost barriers, regulatory oversight |
| Europe |
Moderate |
Reimbursement policies |
| Asia-Pacific |
High |
Limited awareness, pricing pressures |
Key Takeaways
- The drug’s market is growing mainly due to its safety profile and procedural efficiency.
- The high price limits adoption in cost-sensitive healthcare systems.
- Competition from established agents like midazolam and propofol constrains market expansion.
- Price projections indicate a steady increase with potential plateauing as generics or biosimilars emerge.
FAQs
Q1: What are the main advantages of remimazolam over other sedatives?
Quick onset and offset, reduced risk of respiratory depression, and fewer postoperative side effects.
Q2: What factors could influence remimazolam’s price trajectory?
Patent expiry, competition from generics, biosimilars, and changes in healthcare reimbursement policies.
Q3: How does remimazolam's adoption vary geographically?
It remains primarily used in North America and Europe; adoption is slower in Asia-Pacific due to cost and regulatory hurdles.
Q4: What is the potential for price reduction in the next five years?
Likely limited until patent expiry; eventual price decreases possible with biosimilar entries.
Q5: Are there upcoming regulatory changes that could impact market size?
Potential approvals in additional markets (e.g., Japan, China) could expand use, but localized regulatory dynamics could slow growth.
References
[1] Acacia Pharma. (2023). Remimazolam Regulatory and Market Updates.
[2] IQVIA. (2022). Pharmaceutical Market Data.
[3] Market Research Future. (2022). Global Sedatives Market Analysis.
[4] U.S. Food and Drug Administration. (2020). Remimazolam NDA Approval.
[5] EvaluatePharma. (2023). Forecasts for Anesthetic Agents.
